Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
740 stopped studies mapped to Myeloproliferative Neoplasm and descendants · 88% state a reason
Over the 740 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03123588 | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia… | Phase 2 | terminated | Apr 21, 2017 | Incyte Corporation | Enrollment issues | Enrollment / accrual |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and…(PAC326) | Phase 3 | terminated | Feb 5, 2014 | CTI BioPharma | not stated | Not stated |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given… | Phase 1 / Phase 2 | terminated | Mar 5, 2014 | Teva Branded Pharmaceutical Products R&D, Inc. | Inability to accrue additional sites and enroll an adequate number of subjects. | Enrollment / accrual |
| NCT00210119 | Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in…(AFR22) | Phase 2 | terminated | Sep 21, 2005 | Institut Bergonié | not stated | Not stated |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic… | Phase 2 | terminated | Jun 15, 2012 | OHSU Knight Cancer Institute | Unable to recruit enough eligible subjects | Enrollment / accrual |
| NCT02770820 | Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly… | Phase 1 / Phase 2 | terminated | May 12, 2016 | Fred Hutchinson Cancer Center | Terminated due to funding difficulties | Funding |
| NCT04051996 | GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older… | Phase 2 | terminated | Aug 9, 2019 | Yale University | Unable to accrue patients following COVID-19 study pause. | COVID-19 / pandemic |
| NCT00766779 | HCT Versus CT in Elderly AML | Phase 3 | terminated | Oct 6, 2008 | European Society for Blood and Marrow Transplantation | Recommendation of DMC | Other (stated, no rule matched) |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine… | Phase 1 | terminated | Dec 18, 2014 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT02298166 | Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or… | Phase 3 | terminated | Nov 21, 2014 | University of Ulm | The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support of an… | Drug supply |
| NCT00900120 | Collecting and Storing Blood Samples From Patients With Cancer | — | withdrawn | May 12, 2009 | University of Medicine and Dentistry of New Jersey | Will be replaced by honest broker program | Other (stated, no rule matched) |
| NCT03473457 | CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia(AML) | N/A | terminated | Mar 22, 2018 | Zhujiang Hospital | The therapeutic effect was not as expected | Other (stated, no rule matched) |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | Phase 2 | terminated | Jan 11, 2010 | University of Liege | recruitment too slow | Enrollment / accrual |
| NCT02105116 | AML Therapy With Irradiated Allogeneic Cells | N/A | terminated | Apr 7, 2014 | Rutgers, The State University of New Jersey | No patients were eligible to receive the experimental component of the protocol therapy. | Other (stated, no rule matched) |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | Phase 1 | terminated | Aug 13, 2012 | Gilead Sciences | PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD… | Safety / toxicity |
| NCT02229266 | Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy…(HINKL) | Phase 2 | terminated | Sep 1, 2014 | Technische Universität Dresden | low recruitment rate | Enrollment / accrual |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | terminated | Apr 30, 2010 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT04296214 | Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic… | — | withdrawn | Mar 5, 2020 | Grupo Cooperativo de Hemopatías Malignas | Poor recruitment | Enrollment / accrual |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in… | Phase 1 / Phase 2 | terminated | May 12, 2015 | University of Illinois at Chicago | not stated | Not stated |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute… | Phase 1 / Phase 2 | terminated | Dec 7, 2011 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03806192 | Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid… | N/A | terminated | Jan 16, 2019 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT04395092 | Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and… | Phase 2 | withdrawn | May 20, 2020 | Kiadis Pharma | The sponsor decided to withdraw this study | Sponsor / business decision |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host… | Phase 2 / Phase 3 | terminated | Aug 27, 2009 | Kiadis Pharma | not stated | Not stated |
| NCT01131325 | Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations(MACS1148) | Phase 4 | terminated | May 26, 2010 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT03066466 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD… | Phase 3 | withdrawn | Feb 28, 2017 | Loyola University | No participants were enrolled | Enrollment / accrual |
| NCT01599429 | Study of the Predictive Marker FLT in Patients Suffering From AML(TEP-FLT-LMA) | — | withdrawn | May 16, 2012 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | No participants enrolled | Enrollment / accrual |
| NCT01685411 | Busulfan and Cyclophosphamide Followed By ALLO BMT | N/A | terminated | Sep 14, 2012 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT03125876 | A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) | Phase 1 | terminated | Apr 24, 2017 | Sunshine Lake Pharma Co., Ltd. | Company strategy adjustment | Sponsor / business decision |
| NCT03360006 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With… | Phase 1 | terminated | Dec 2, 2017 | AbbVie | Strategic Reasons | Sponsor / business decision |
| NCT02648932 | The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With… | Phase 2 | terminated | Jan 7, 2016 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | Phase 1 / Phase 2 | terminated | Apr 13, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03881735 | Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With… | Phase 2 | withdrawn | Mar 19, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT04283526 | Study of Select Combinations in Adults With Myelofibrosis | Phase 1 | withdrawn | Feb 25, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT02973711 | A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | Phase 1 / Phase 2 | withdrawn | Nov 25, 2016 | University of Michigan Rogel Cancer Center | lack of funding | Funding |
| NCT03515707 | Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal… | Phase 2 | withdrawn | May 3, 2018 | Fred Hutchinson Cancer Center | PI recommended closure | Other (stated, no rule matched) |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT00615784 | Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407) | Phase 2 | terminated | Feb 14, 2008 | Abramson Cancer Center at Penn Medicine | Study terminated. Eisai's Targretin acquired by another pharmaceutical company. | Sponsor / business decision |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell… | Phase 2 | terminated | Oct 17, 2018 | Milton S. Hershey Medical Center | Funding pulled | Funding |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT02782403 | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase… | Phase 1 | terminated | May 25, 2016 | M.D. Anderson Cancer Center | Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to… | Enrollment / accrual |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or… | Phase 1 / Phase 2 | withdrawn | Jul 30, 2020 | M.D. Anderson Cancer Center | The original sponsor was acquired by a new company and has elected to end funding for all… | Investigator |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | Phase 1 / Phase 2 | terminated | Aug 2, 2012 | PrECOG, LLC. | Study stopped per Novartis request due to futility from another study. | Efficacy / futility |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Nov 2, 2016 | M.D. Anderson Cancer Center | PDOL request | Other (stated, no rule matched) |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | Phase 1 | terminated | Apr 25, 2016 | Washington University School of Medicine | Toxicity. Only enrolled patients in phase I portion of trial. | Safety / toxicity |
| NCT04128020 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation… | Phase 1 | withdrawn | Oct 16, 2019 | Sherif Farag | Funder withdrew funding after not accruing any subjects after 1 year. | Enrollment / accrual |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | Phase 3 | terminated | Jan 23, 2013 | CTI BioPharma | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 19, 2021source: clinicaltrials